Oral Micronized Progesterone for Adolescents (12 to 17): Transition to Adult Care

Why Transition Planning Matters for Adolescents on Progesterone

Young people aged 12 to 17 on oral micronized progesterone face a convergence of biological and logistical pressures right when adult care begins. Bone density, cardiovascular risk trajectories, and fertility preservation all hinge on keeping progesterone therapy uninterrupted.

Transition from pediatric to adult care is not a single handoff appointment. The American Academy of Pediatrics defines it as a purposeful, planned movement that begins no later than age 14 and runs through the mid-20s. For adolescents on Prometrium, any gap in therapy during this window can mean missed menstrual cycles, accelerated bone loss, or estrogen-only exposure in patients who need progestogen opposition to protect the uterine lining [1].

The Dropout Problem Is Real

Data from longitudinal studies of adolescents with chronic conditions show that 40 to 50% disengage from specialty care in the 18-to-25 age bracket [2]. For patients on hormone therapy, a 3-month gap in progesterone can blunt the cyclic endometrial shedding needed to prevent endometrial hyperplasia in those on estrogen replacement, and it can suppress bone turnover markers that are still rising toward peak values in the early 20s.

What "Transition" Actually Includes

Transition planning for an adolescent on oral micronized progesterone covers four distinct domains:

• Medical continuity: Ensuring the adult provider has full records, current lab values, and the exact Prometrium dosing schedule.
• Pharmacy continuity: Confirming that the adult formulary covers Prometrium or an equivalent micronized progesterone formulation.
• Insurance continuity: Verifying that the patient's insurance plan does not require a prior authorization reset when they move from a pediatric to an adult network.
• Self-management skills: Teaching the patient to order refills, recognize missed-dose symptoms, and communicate with a new provider independently.

Indications for Oral Micronized Progesterone in the 12 to 17 Age Group

Prometrium is used in adolescents across three main clinical scenarios, each with different dosing logic and different transition considerations.

Primary Ovarian Insufficiency (POI)

The Endocrine Society's 2023 Clinical Practice Guideline on POI recommends hormone replacement therapy beginning at the time of diagnosis, regardless of age, to preserve bone density and cardiovascular health [3]. Adolescents diagnosed with POI (defined as ovarian dysfunction before age 40 with FSH above 25 IU/L on two measurements at least 4 weeks apart) are typically started on cyclic oral micronized progesterone 200 mg nightly for 12 to 14 days per month alongside estrogen replacement.

The Endocrine Society guideline states directly: "We recommend estrogen-progestogen therapy in women with POI who have a uterus, to induce or maintain secondary sex characteristics and to prevent bone loss" [3].

At transition to adult care, the adult gynecologist or endocrinologist must receive documentation of:

• Age at POI diagnosis
• Current Prometrium dose and cycle day schedule
• Most recent FSH, LH, and estradiol values
• Most recent DXA scan result and Z-score

Gender-Affirming Hormone Therapy

Adolescents assigned female at birth who are pursuing gender-affirming care may receive oral micronized progesterone as part of a broader hormone regimen. Prescribing in this setting is individualized, off-label, and guided by the World Professional Association for Transgender Health (WPATH) Standards of Care Version 8, which recommends that hormone therapy in minors be initiated only with appropriate consent processes and multidisciplinary support [4].

Progesterone's role in gender-affirming therapy for transmasculine adolescents who have not yet undergone surgical interventions remains debated. Some clinicians prescribe cyclic progesterone to induce scheduled withdrawal bleeds while testosterone levels are still sub-therapeutic. The transition to adult gender-affirming care should include a warm handoff to an adult provider who is credentialed in WPATH-aligned care and familiar with both the endocrine and psychosocial components of ongoing management.

Abnormal Uterine Bleeding and Secondary Amenorrhea

ACOG Practice Bulletin 128 identifies progestin therapy as first-line for management of anovulatory bleeding in adolescents [5]. Oral micronized progesterone 200 mg for 12 days per month provides a cyclic withdrawal bleed, re-establishing a regular pattern in adolescents with hypothalamic amenorrhea or polycystic ovary syndrome (PCOS). When these patients age out of pediatric gynecology, the adult provider needs the full history of cycle response, prior endometrial ultrasound results, and any prior hormonal workup.

Dosing Reference for the Transition Period

Dose does not automatically change at age 18. The adult team should review the current regimen and confirm it fits the adult indication before modifying anything.

| Indication | Typical Adolescent Dose | Notes at Transition | |---|---|---| | POI (cyclic) | 200 mg orally at bedtime, days 1 to 12 of each month | Confirm estrogen dose is also age-appropriate for adult levels | | POI (continuous combined) | 100 mg orally nightly | Used when withdrawal bleeds are not desired | | Gender-affirming (off-label) | 100 to 200 mg nightly, individualized | Document WPATH-aligned consent at transfer | | AUB / secondary amenorrhea | 200 mg nightly for 12 days per cycle | Reassess underlying diagnosis at adult intake |

Prometrium capsules contain peanut oil. The FDA label carries a precaution for patients with peanut allergy [6]. This fact must appear in every transition summary, because adult prescribers who are unfamiliar with the patient's history may not check allergy documentation against inactive ingredients.

Bone Health: The Non-Negotiable Priority

Bone is why progesterone gaps are dangerous in this age group. Peak bone mineral density is reached between ages 20 and 25, and the years from 14 to 22 are the most productive for bone accrual [7]. A 6-month gap in hormone therapy during this window may not be clinically silent.

DXA Monitoring Schedule

The Endocrine Society recommends DXA scanning at diagnosis for adolescents with POI, with repeat scans every 1 to 2 years if a Z-score is below minus 2.0, or every 2 to 3 years if Z-scores are in the expected range [3]. Adult providers must receive the most recent DXA report and understand that adolescent bone density is compared against Z-scores (age-matched peers), not T-scores (young adult peak), because the skeleton has not yet matured.

What a Progesterone Gap Does to Bone

Progesterone receptors are expressed on osteoblasts. In vitro data and animal models have consistently shown that progesterone promotes osteoblast differentiation and may reduce bone resorption [8]. Clinical data in humans are less definitive, but observational studies in adolescents with POI confirm that combined estrogen-progestogen therapy maintains lumbar spine Z-scores significantly better than no therapy or estrogen alone [9].

Calcium and Vitamin D as Adjuncts

Adolescents on hormone replacement for POI should also receive calcium 1,000 to 1,300 mg daily and vitamin D 600 to 800 IU daily per NIH Office of Dietary Supplements recommendations. The adult provider should document whether the patient is meeting these targets at the first adult visit.

Building the Transition Roadmap: Ages 14 to 19

A well-designed transition follows a predictable timeline. The following framework is adapted from the AAP/AAFP/ACP joint consensus statement on transition from pediatric to adult care [10].

Ages 14 to 15: Awareness Phase

• Introduce the concept of adult care to both patient and family.
• Begin teaching the patient their own Prometrium dose, cycle-day schedule, and the reason they take it.
• Document any barriers to adult care access, including insurance type, geographic access, and language.

Ages 16 to 17: Skills-Building Phase

• The patient should be able to contact the pharmacy independently and recognize when a refill is due.
• The patient should be able to describe their diagnosis and current hormone regimen to a new provider without parental prompting.
• Identify and, if possible, establish care with an adult gynecologist or endocrinologist before the patient turns 18.
• Request a "pre-transfer" consultation with the adult provider so records can be reviewed before the formal handoff.

Age 17 to 18: Transfer Phase

• Complete a written transition summary that includes: diagnosis, Prometrium dose, cycle schedule, last lab values (FSH, LH, estradiol, serum progesterone), last DXA result, peanut allergy status, and any prior adverse effects.
• Confirm that the adult provider has received and reviewed the summary.
• Confirm pharmacy formulary coverage under the patient's adult insurance plan.
• Schedule the first adult endocrine or gynecology appointment before the last pediatric visit.

Age 18 to 19: Consolidation Phase

• The adult provider performs a full intake, reviews all prior records, and independently confirms the diagnosis and current regimen.
• Repeat FSH, LH, and estradiol at first adult visit if labs are more than 6 months old.
• Schedule DXA within 12 months of transfer if not done in the prior 2 years.

Insurance and Pharmacy Continuity

Insurance is a practical barrier that derails otherwise well-planned transitions. Under the Affordable Care Act, dependent children may remain on a parent's plan until age 26, but this does not guarantee formulary continuity or network continuity [11]. An adolescent who moves from a pediatric network to an adult network may suddenly face a prior authorization requirement for Prometrium that their pediatric prescriber never needed.

Steps to prevent a coverage gap:

1. Check the adult formulary for Prometrium at least 3 months before transfer.
2. If Prometrium is not on the adult formulary, identify the covered equivalent (generic oral micronized progesterone 100 mg or 200 mg capsules are bioequivalent to Prometrium and contain the same peanut-oil base).
3. Request a bridge supply of 90 days from the pediatric prescriber to cover the gap between last pediatric visit and first adult prescription.
4. If prior authorization is required, begin the process before the patient turns 18 so adult prescriber credentials are in place.

The FDA's Prometrium labeling confirms that the brand and generic oral micronized progesterone formulations are therapeutically equivalent for the approved indications [6]. Switching from brand to generic does not require a dose adjustment, but patients should be counseled to check inactive ingredients with the pharmacist to confirm that the generic also uses peanut oil as the capsule fill medium.

What the Adult Provider Needs on Day One

The first adult appointment is not the time to reconstruct a patient's hormone history from memory. The transition summary handed off from the pediatric team should be a single document that lets the adult provider confirm the regimen without a phone call back to the prior practice.

A complete transfer summary for an adolescent on oral micronized progesterone includes:

• Full diagnosis with ICD-10 code (e.g., E28.39 for POI)
• Current Prometrium dose and schedule (e.g., 200 mg orally at bedtime days 1 to 12 of each month)
• Concomitant estrogen therapy if applicable (dose, route, brand or generic)
• Last laboratory values with dates: FSH, LH, estradiol, serum progesterone (day-21 if applicable)
• Last DXA result with Z-scores at lumbar spine and total hip
• Allergy documentation: peanut allergy status explicitly stated
• Prior adverse effects: sedation from progesterone (a common dose-related effect at 200 mg), breakthrough bleeding, or GI intolerance
• Fertility goals: whether the patient has discussed future fertility intentions
• Psychosocial context: any mental health diagnoses, social support status, adherence history

Adherence and Self-Efficacy in the Transition Window

Adolescents are not small adults. The neurobiological development of the prefrontal cortex, which governs long-term planning and medication adherence, continues until approximately age 25 [12]. This matters clinically because progesterone dosing is often cyclic, meaning the patient must track cycle days and restart the medication at a specific time each month. Missing the start day by more than 2 to 3 days disrupts the planned withdrawal bleed and may result in unpredictable spotting.

Practical Adherence Tools

• Smartphone calendar reminders set to repeat monthly on the cycle start day
• Pharmacy blister packs or pill organizers labeled by day
• A written "sick day" and "missed dose" protocol from the prescribing physician, given to the patient at every annual visit

A missed single dose of Prometrium at bedtime should be taken the next morning if the patient remembers within 12 hours, or skipped if more than 12 hours have passed. The patient should not double-dose [6]. This instruction appears in the FDA label and should be included in every patient education sheet at transfer.

Family Involvement Calibration

Parental involvement in medication management should taper deliberately between ages 14 and 18. By age 16, the patient should be filling their own prescriptions. By age 18, the patient should be the primary contact for the pharmacy and the new adult provider's patient portal. Adult providers who continue to communicate exclusively with parents risk leaving the patient without self-management skills when they eventually live independently.

Monitoring Labs After Transfer: A Practical Schedule

Adult providers who are not familiar with this patient population may not know which labs to order or how often. The following schedule is consistent with Endocrine Society and ACOG recommendations [3] [5]:

| Timepoint | Labs | Purpose | |---|---|---| | First adult visit | FSH, LH, estradiol, serum progesterone | Confirm adequacy of current regimen | | Every 6 to 12 months (POI) | FSH, LH, estradiol | Monitor ovarian function and estrogen adequacy | | Every 1 to 2 years | DXA (lumbar spine and hip) | Track bone mineral density during accrual years | | Annually | Blood pressure, BMI, fasting glucose | Cardiovascular and metabolic risk surveillance | | As indicated | Thyroid function (TSH), adrenal antibodies | Autoimmune associations with POI |

POI has a 20 to 40% association with autoimmune thyroid disease and a lower but real association with adrenal insufficiency [3]. Adult providers picking up a patient with POI should screen for these at the first visit if not done within the prior 12 months.

Special Considerations: Gender-Affirming Care Transitions

For transmasculine adolescents on oral micronized progesterone as part of gender-affirming hormone therapy, the adult care transition carries additional considerations. The adolescent may be simultaneously transitioning their primary care, their endocrinology or gynecology care, and their mental health care. Each of those handoffs should be coordinated rather than happening sequentially over months.

WPATH Standards of Care Version 8 recommends that gender-affirming care be "integrated and longitudinal," with explicit planning for the transition from adolescent to adult services [4]. An adult provider taking over gender-affirming hormone therapy should review the original informed consent documentation, the current testosterone dose (if applicable), and the role that progesterone is currently playing in the regimen before making any changes.

The Endocrine Society's 2017 Clinical Practice Guideline on Gender-Dysphoric/Gender-Incongruent Persons recommends continued monitoring of bone density and hormonal levels throughout the adult transition, particularly in patients who have not yet reached skeletal maturity [13].

Common Adverse Effects to Anticipate and Communicate at Transfer

Prometrium at 200 mg has a documented sedating effect because progesterone is metabolized to neurosteroids, including allopregnanolone, which potentiate GABA-A receptors [14]. This is why the drug is dosed at bedtime. The adult provider should know this to avoid interpreting daytime somnolence reports as a reason to change therapy, and to understand why the bedtime schedule is not arbitrary.

Other effects the adult team should document:

• Breast tenderness, typically in the luteal phase of cyclic dosing
• Bloating or nausea in the first month of therapy, which usually resolves
• Breakthrough bleeding if doses are missed or timing is irregular
• Dizziness if the patient takes the capsule with food that delays gastric emptying

None of these are reasons to discontinue therapy without discussion. Each should be addressed in the transition summary so the adult provider can distinguish expected effects from new adverse events.